Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity.
暂无分享,去创建一个
Gerhard Wolber | Evi Kostenis | Marcel Bermudez | Ulrike Holzgrabe | U. Holzgrabe | G. Wolber | E. Kostenis | K. Mohr | C. Tränkle | M. Bermudez | R. Schrage | Klaus Mohr | D. van der Mey | Jens Schmitz | Ramona Schrage | Christian Tränkle | Dorina van der Mey | Jessica Klöckner | J. Klöckner | Jens Schmitz | Gerhard Wolber
[1] P. Conti,et al. Synthesis and functional characterization of novel derivatives related to oxotremorine and oxotremorine-M. , 1999, Bioorganic & medicinal chemistry.
[2] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[3] K. Mohr,et al. Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. , 2002, Molecular pharmacology.
[4] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[5] P. Sexton,et al. The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-coupled receptors. , 2012, Annual review of pharmacology and toxicology.
[6] Thierry Langer,et al. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..
[7] U. Holzgrabe,et al. Elevation of ligand binding to muscarinic M(2) acetylcholine receptors by bis(ammonio)alkane-type allosteric modulators. , 2002, Journal of medicinal chemistry.
[8] Albert C. Pan,et al. Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.
[9] U. Holzgrabe,et al. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling , 2012, Nature Communications.
[10] U. Holzgrabe,et al. Allosteric Small Molecules Unveil a Role of an Extracellular E2/Transmembrane Helix 7 Junction for G Protein-coupled Receptor Activation* , 2007, Journal of Biological Chemistry.
[11] H. Schneider,et al. Konformationen und N‐Inversionsbarrieren in Tropanverbindungen , 1976 .
[12] Federico D. Sacerdoti,et al. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters , 2006, ACM/IEEE SC 2006 Conference (SC'06).
[13] U. Holzgrabe,et al. M1 muscarinic cetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimer's disease , 2012 .
[14] O. Wassermann,et al. Inhibition of the actions of carbachol and DFP on guinea pig isolated atria by alkane-bis-ammonium compounds. , 1969, European journal of pharmacology.
[15] Albert C. Pan,et al. Pathway and mechanism of drug binding to G-protein-coupled receptors , 2011, Proceedings of the National Academy of Sciences.
[16] A. Kruse,et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist , 2011, Nature.
[17] J. Wess,et al. Activation and allosteric modulation of a muscarinic acetylcholine receptor , 2013, Nature.
[18] Modes of allosteric interactions with free and [3H]N-methylscopolamine-occupied muscarinic M2 receptors as deduced from buffer-dependent potency shifts , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.
[19] G. Milligan,et al. Applying label-free dynamic mass redistribution technology to frame signaling of G protein–coupled receptors noninvasively in living cells , 2011, Nature Protocols.
[20] Jonathan A. Javitch,et al. Structure of the Human Dopamine D3 Receptor in Complex with a D2/D3 Selective Antagonist , 2010, Science.
[21] J. Ballesteros,et al. [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .
[22] J. Galzi,et al. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. , 2004, Journal of medicinal chemistry.
[23] N. Birdsall,et al. Muscarinic receptor subtypes. , 1990, Annual review of pharmacology and toxicology.
[24] U. Holzgrabe,et al. Convergent, short synthesis of the muscarinic superagonist iperoxo , 2010 .
[25] M. Brann,et al. Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. , 1991, Biochemical pharmacology.
[26] U. Holzgrabe,et al. Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor , 2013, British journal of pharmacology.
[27] U. Holzgrabe,et al. Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor. , 2014, Nature chemical biology.
[28] U. Holzgrabe,et al. Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity. , 2014, European journal of medicinal chemistry.
[29] S. Rasmussen,et al. Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.
[30] Esther Kellenberger,et al. Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors. , 2012, Journal of medicinal chemistry.
[31] K. Mohr,et al. Dualsteric GPCR targeting and functional selectivity: the paradigmatic M(2) muscarinic acetylcholine receptor. , 2013, Drug discovery today. Technologies.
[32] U. Holzgrabe,et al. Design, synthesis, and action of oxotremorine-related hybrid-type allosteric modulators of muscarinic acetylcholine receptors. , 2006, Journal of medicinal chemistry.
[33] Andrei L. Lomize,et al. OPM: Orientations of Proteins in Membranes database , 2006, Bioinform..
[34] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[35] F. Ehlert,et al. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. , 1988, Molecular pharmacology.
[36] Arthur Christopoulos,et al. A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity , 2008, Journal of Biological Chemistry.
[37] U. Holzgrabe,et al. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[38] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[39] F. Mitchelson,et al. THE INHIBITORY EFFECT OF GALLAMINE ON MUSCARINIC RECEPTORS , 1976, British journal of pharmacology.
[40] U. Holzgrabe,et al. A Fast and Efficient Track to Allosteric Modulators of Muscarinic Receptors: Microwave-Assisted Syntheses , 2007 .
[41] Thierry Langer,et al. Efficient overlay of small organic molecules using 3D pharmacophores , 2007, J. Comput. Aided Mol. Des..
[42] H. Motulsky,et al. Calculating receptor number from binding experiments using same compound as radioligand and competitor. , 1989, Trends in pharmacological sciences.
[43] E. Kostenis,et al. Two-point kinetic experiments to quantify allosteric effects on radioligand dissociation. , 1996, Trends in pharmacological sciences.
[44] M. Burghammer,et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.
[45] U. Holzgrabe,et al. Allosteric ligands for G protein‐coupled receptors: A novel strategy with attractive therapeutic opportunities , 2010, Medicinal research reviews.
[46] U. Holzgrabe,et al. Systematic development of high affinity bis(ammonio)alkane-type allosteric enhancers of muscarinic ligand binding. , 2003, Journal of medicinal chemistry.
[47] R. Glaser,et al. Stereochemistry of the N-methyl group in salts of tropane alkaloids , 1988 .
[48] C. Cavallito,et al. The Preparation of Some ι-Bromoalkyl Quaternary Ammonium Salts , 1955 .
[49] Ruben Abagyan,et al. Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.
[50] Ulrike Holzgrabe,et al. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. , 2013, Angewandte Chemie.
[51] Edith Heilbronn,et al. Muscarinic acetylcholine receptor , 1978, Progress in Neurobiology.
[52] R. Glen,et al. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.
[53] U. Holzgrabe,et al. Muscarinic allosteric enhancers of ligand binding: pivotal pharmacophoric elements in hexamethonio-type agents. , 2005, Journal of medicinal chemistry.
[54] N. Birdsall,et al. Modification of the binding properties of muscarinic receptors by gallamine. , 1983, Molecular pharmacology.
[55] M. Impicciatore,et al. New analogues of oxotremorine and oxotremorine-M: estimation of their in vitro affinity and efficacy at muscarinic receptor subtypes. , 2000, Life sciences.
[56] Vadim Cherezov,et al. Diversity and modularity of G protein-coupled receptor structures. , 2012, Trends in pharmacological sciences.
[57] K. Mohr,et al. Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and Cooperativity , 2006, Molecular Pharmacology.
[58] John Ellis,et al. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. , 2003, Molecular pharmacology.